Agents targeting ras signaling pathwayDANCEY, J. E.Current pharmaceutical design. 2002, Vol 8, Num 25, pp 2259-2267, issn 1381-6128, 9 p.Article

Recommendations for the assessment of progression in randomised cancer treatment trialsDANCEY, J. E; DODD, L. E; FORD, R et al.European journal of cancer (1990). 2009, Vol 45, Num 2, pp 281-289, issn 0959-8049, 9 p.Article

Validation of novel imaging methodologies for use as cancer clinical trial end-pointsSARGENT, D. J; RUBINSTEIN, L; SCHWARTZ, L et al.European journal of cancer (1990). 2009, Vol 45, Num 2, pp 290-299, issn 0959-8049, 10 p.Article

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers : a Princess Margaret Hospital Phase II Consortium studyHOTTE, S. J; OZA, A; WINQUIST, E. W et al.Annals of oncology. 2006, Vol 17, Num 2, pp 334-340, issn 0923-7534, 7 p.Article

Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancerLEIGHL, Natasha B; GOSS, G. D; SHEPHERD, F. A et al.Lung cancer. 2006, Vol 52, Num 3, pp 327-332, issn 0169-5002, 6 p.Article

Molecular targeting: PI3 kinase pathwayDANCEY, J. E.Annals of oncology. 2004, Vol 15, pp iv233-iv239, issn 0923-7534, SUP4Conference Paper